Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 4:50 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1537–1560 of 16,834 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Symptom Clusters Clear all

Conditions: Hereditary Angioedema
Interventions: Donidalorsen; Drug
Lead sponsor: Ionis Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 6
States / cities: Scottsdale, Arizona • Santa Monica, California • Plymouth, Minnesota + 3 more

Conditions: Congenital Diaphragmatic Hernia, Persistent Pulmonary Hypertension of the Newborn, Hypoxemic Respiratory Failure, Pulmonary Hypoplasia
Interventions: Milrinone, Placebo (5% Dextrose); Drug
Lead sponsor: NICHD Neonatal Research Network; Network
Eligibility: 0 Hours to 168 Hours
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2025
U.S. locations: 19
States / cities: Birmingham, Alabama • Palo Alto, California • Atlanta, Georgia + 15 more

Conditions: Obstructive Sleep Apnea
Interventions: Immediate Intervention, Waitlist control; Behavioral
Lead sponsor: VA Greater Los Angeles Healthcare System; Federal
Eligibility: 21 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: North Hills, California

Conditions: Caregiver Stress Syndrome, Anxiety
Interventions: Mindfulness Coach, Active Comparator; Behavioral
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 21 Years and older
Enrollment: 162 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 3
States / cities: Livingston, New Jersey • Monroe, New Jersey • New Brunswick, New Jersey

Conditions: Obstructive Sleep Apnea (OSA)
Interventions: Placebo oral capsule, DAW1033D oral capsule; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 21 Years to 65 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Short Bowel Syndrome, Short Gut Syndrome, SBS, Short Gut
Interventions: 0.6 mL, MP-101 (10 mg/mL, Opium Tincture (OT)), USP (Deodorized); Drug
Lead sponsor: Marathon Pharmaceuticals, LLC; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 5
States / cities: Chicago, Illinois • Indianapolis, Indiana • Cleveland, Ohio + 2 more

Conditions: HIV Infections, Depression
Interventions: Bupropion, Placebo; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older · Male only
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2004
U.S. locations: 2
States / cities: New York, New York

Conditions: Hematological Malignancy, Acute Leukemia in Remission, Acute Lymphoblastic Leukemia in Remission, Myelodysplastic Syndromes, Non-Hodgkin Lymphoma, Hodgkin Lymphoma
Interventions: Cord blood stem cells, Valproic Acid, Fludarabine, cytoxan, Thiotepa, TBI; Biological · Drug
Lead sponsor: Alla Keyzner; Other
Eligibility: 18 Years to 65 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: Genitourinary Syndrome of Menopause (GSM)
Interventions: Revaree, Estrace; Device · Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 100 Years · Female only
Enrollment: 49 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: New York, New York

Conditions: HIV Infections, Substance Use
Interventions: Peer Activate-LAI, Standard of Care HIV treatment or prevention with LAI-PrEP/ART; Behavioral · Other
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 88 Years
Enrollment: 186 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2028
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • Baltimore, Maryland

Conditions: Celiac Disease
Interventions: ALV003, placebo; Drug
Lead sponsor: Alvine Pharmaceuticals Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 79
States / cities: Decatur, Alabama • Huntsville, Alabama • Scottsdale, Arizona + 70 more

Conditions: Irritable Bowel Syndrome, Ulcerative Colitis, Interstitial Cystitis, Prostatitis, Pelvic Pain
Interventions: Gralise; Drug
Lead sponsor: Shirley Ryan AbilityLab; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: HIV Infections
Interventions: Indinavir sulfate, Delavirdine mesylate, Zidovudine; Drug
Lead sponsor: Pharmacia and Upjohn; Industry
Eligibility: 14 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 6
States / cities: Los Angeles, California • San Francisco, California • New York, New York + 3 more

Conditions: Generalized Myasthenia Gravis
Interventions: zilucoplan (RA101495); Drug
Lead sponsor: UCB Biopharma SRL; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 33
States / cities: Mobile, Alabama • Phoenix, Arizona • Irvine, California + 29 more

Conditions: Metastatic Colorectal Carcinoma (mCRC), Colorectal Cancer (CRC), Adenomatous Polyposis Coli (APC) Gene Mutation, Catenin Beta-1 (CTNNB1) Gene Mutation
Interventions: Tegavivint; Drug
Lead sponsor: HonorHealth Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 126 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Scottsdale, Arizona

Conditions: Turner Syndrome, Hypogonadism, Premature Ovarian Failure
Interventions: 17 beta estradiol; Drug
Lead sponsor: Nemours Children's Clinic; Other
Eligibility: 10 Years to 16 Years · Female only
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2004
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: HIV Infections
Interventions: Tamoxifen, Vorinostat, Antiretroviral drugs; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 14
States / cities: Birmingham, Alabama • Los Angeles, California • San Francisco, California + 11 more

Conditions: Malaria
Interventions: VRC-MALMAB0100-00-AB, Plasmodium falciparum (P. falciparum) sporozoite challenge; Drug · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 71 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 2
States / cities: Baltimore, Maryland • Bethesda, Maryland

Conditions: Fanconi's Anemia
Interventions: anti-thymocyte globulin, cyclophosphamide, cyclosporine, filgrastim, fludarabine, methylprednisolone; Drug
Lead sponsor: University of Minnesota; Other
Eligibility: 0 Years to 34 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Overactive Bladder Syndrome
Interventions: Device Morpheus8V; Device
Lead sponsor: InMode MD Ltd.; Industry
Eligibility: 21 Years to 80 Years · Female only
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 2
States / cities: Corona del Mar, California • Knoxville, Tennessee

Conditions: HIV Infections
Interventions: Profectus HIV MAG pDNA vaccine, IL-12, Placebo; Biological · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 55 Years
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 13
States / cities: Los Angeles, California • Palo Alto, California • San Francisco, California + 8 more

Conditions: Polycystic Ovarian Syndrome
Interventions: IVM; Other
Lead sponsor: University Reproductive Associates; Other
Eligibility: 18 Years to 34 Years · Female only
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 2
States / cities: Hasbrouck Heights, New Jersey • Hoboken, New Jersey

Conditions: Cancer
Interventions: vorinostat; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2008
U.S. locations: 1
States / cities: New York, New York

Conditions: Angelman Syndrome, Nervous System Diseases
Interventions: Betaine, Creatine, Metafolin, Vitamin B12; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 1 Day to 5 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 4
States / cities: San Diego, California • Boston, Massachusetts • Greenwood, South Carolina + 1 more

Search by objective public record fields.

An Extension Study of Donidalorsen (IONIS-PKK-LRx) in Participants With Hereditary Angioedema

Milrinone in Congenital Diaphragmatic Hernia

Chronic Care Management With Wearable Devices in Patients Prescribed Positive Airway Pressure Therapy (mPAP) Trial

mHealth Mindfulness With Patients With Serious Illness and Their Caregivers

DAW1033D in Obstructive Sleep Apnea

A Open Label Extension Study for Subjects That Complete Study MP-101-CL-001

Bupropion For Reducing High-Risk Behaviors in Depressed Men Who Have Sex With Men (MSM)

VPA Expanded UCB Transplantation for Treatment of Patients With Hematological Malignancies

A Randomized, Single Center Pilot Study Comparing Hyaluronic Acid to Vaginal Estrogen for Treatment of Genitourinary Syndrome of Menopause

Peer Behavioral Activation Utilization to Improve Substance Use and HIV Outcomes in People Receiving Long Acting Injectable-PrEP/ART (PUSH)

Evaluation of the Efficacy and Safety of ALV003 in Symptomatic in Celiac Disease Patients

Efficacy of Gralise® for Chronic Pelvic Pain

A Study to Find the Best Dosing Schedule for Delavirdine, Zidovudine, and Indinavir in HIV-Positive Patients

Open-Label Extension of Zilucoplan in Subjects With Generalized Myasthenia Gravis

Safety and Efficacy of Tegavivint in Patients With Metastatic Colorectal Carcinoma

Estrogen Treatment (Oral vs. Patches) in Turner Syndrome

Selective Estrogen Receptor Modulators to Enhance the Efficacy of Viral Reactivation With Histone Deacetylase Inhibitors

Trial to Evaluate CIS43LS in Healthy Adults

Phase I/II Study of Total Body Irradiation, Cyclophosphamide, and Fludarabine Followed by Alternate Donor Hematopoietic Cell Transplantation in Patients With Fanconi's Anemia

Transvaginal Detrusor Nerve Radiofrequency Ablation for Treatment of Overactive Bladder

Safety of and Immune Response to an Investigational HIV-1 Vaccine With or Without Interleukin-12 (IL-12) in HIV-1 Infected Adults

In Vitro Maturation (IVM) for Polycystic Ovary Syndrome (PCOS)

Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Cancer

Dietary Supplements for the Treatment of Angelman Syndrome